East Windsor, N.J. – Aurobindo Pharma Limited has received final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application for Sildenafil Tablets, 25mg, 50mg, and 100mg. Aurobindo’s Sildenafil Tablets are an AB-rated generic equivalent to the reference listed drug VIAGRA®.

Sildenafil Citrate tablets is indicated for the treatment of erectile dysfunction.

The product has an estimated market size of $1.4B for the twelve months ending April 2018 according to IQVIA*.

Sildenafil Citrate tablets represent the latest addition to Aurobindo’s broad line of vertically integrated generic pharmaceuticals. Aurobindo’s product portfolio consists of 318 final approvals, including 35 tentative approvals, and 17 approved products from Aurolife. There are 105 additional products on file with U.S. FDA.

* IQVIA National Sales Perspectives: Retail and Non-Retail MAT April 2018